Trials / Terminated
TerminatedNCT03711162
A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care
A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of GLPG1690 in Addition to Local Standard of Care for Minimum 52 Weeks in Subjects With Idiopathic Pulmonary Fibrosis
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 525 (actual)
- Sponsor
- Galapagos NV · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study was to see how GLPG1690 works together with your current standard treatment on your lung function and IPF disease in general. The study also investigated how well GLPG1690 is tolerated (for example if you got any side effects while on study drug).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GLPG1690 | GLPG1690, film-coated tablets for oral use. |
| DRUG | Placebo | Matching placebo, film-coated tablets for oral use. |
Timeline
- Start date
- 2018-11-28
- Primary completion
- 2021-03-30
- Completion
- 2021-03-30
- First posted
- 2018-10-18
- Last updated
- 2022-07-29
- Results posted
- 2022-07-29
Locations
132 sites across 15 countries: United States, Australia, Belgium, Brazil, Chile, Czechia, Denmark, Germany, Greece, Japan, Peru, Spain, Taiwan, Turkey (Türkiye), United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03711162. Inclusion in this directory is not an endorsement.